» Articles » PMID: 35104370

Bone Marrow Findings of Idiopathic Multicentric Castleman Disease: A Histopathologic Analysis and Systematic Literature Review

Overview
Journal Hematol Oncol
Specialties Hematology
Oncology
Date 2022 Feb 1
PMID 35104370
Authors
Affiliations
Soon will be listed here.
Abstract

Idiopathic multicentric Castleman disease (iMCD) is a polyclonal lymphoproliferative disorder characterized by constitutional symptoms, generalized lymphadenopathy, cytopenias, and multi-organ dysfunction due to excessive cytokines, notably Interleukin-6. Idiopathic multicentric Castleman disease is often sub-classified into iMCD-TAFRO, which is associated with thrombocytopenia (T), anasarca (A), fever/elevated C-reactive protein (F), renal dysfunction (R), and organomegaly (O), and iMCD not otherwise specified (iMCD-NOS), which is typically associated with thrombocytosis and hypergammaglobulinemia. The diagnosis of iMCD is challenging as consensus clinico-pathological diagnostic criteria were only recently established and include several non-specific lymph node histopathological features. Identification of further clinico-pathological features commonly found in iMCD could contribute to more accurate and timely diagnoses. We set out to characterize bone marrow (BM) histopathological features in iMCD, assess differences between iMCD-TAFRO and iMCD-NOS, and determine if these findings are specific to iMCD. Examination of BM specimens from 24 iMCD patients revealed a high proportion with hypercellularity, megakaryocytic atypia, reticulin fibrosis, and plasmacytosis across patients with both iMCD-NOS and iMCD-TAFRO with significantly more megakaryocytic hyperplasia (p = 0.001) in the iMCD-TAFRO cases. These findings were also consistent with BM findings from 185 published cases of iMCD-NOS and iMCD-TAFRO. However, these findings are relatively nonspecific as they can be seen in various other infectious, malignant, and autoimmune diseases.

Citing Articles

TAFRO Syndrome: Guidance for Managing Patients Presenting Thrombocytopenia, Anasarca, Fever, Reticulin Fibrosis, Renal Insufficiency, and Organomegaly.

Miura K, Nishimaki-Watanabe H, Takahashi H, Nakagawa M, Otake S, Hamada T Biomedicines. 2024; 12(6).

PMID: 38927484 PMC: 11200895. DOI: 10.3390/biomedicines12061277.


Immune-mediated thrombocytopenia and IL-6-mediated thrombocytosis observed in idiopathic multicentric Castleman disease.

Rubenstein A, Pierson S, Shyamsundar S, Sarmiento Bustamante M, Gonzalez M, Milller I Br J Haematol. 2024; 204(3):921-930.

PMID: 38168727 PMC: 10998476. DOI: 10.1111/bjh.19279.


Unmet Clinical Needs in the Management of Idiopathic Multicentric Castleman Disease: A Consensus-based Position Paper From an ad hoc Expert Panel.

Zinzani P, Paulli M, Arcaini L, Della Torre E, Ferrero S, Figuera A Hemasphere. 2023; 7(6):e891.

PMID: 37234822 PMC: 10208718. DOI: 10.1097/HS9.0000000000000891.


Idiopathic Multicentric Castleman Disease Occurring Shortly after mRNA SARS-CoV-2 Vaccine.

Hoffmann C, Wechselberger T, Drexel H, Dertinger S, Dirnhofer S, Pierson S Vaccines (Basel). 2022; 10(10).

PMID: 36298590 PMC: 9609308. DOI: 10.3390/vaccines10101725.


How we manage idiopathic multicentric Castleman disease.

Brandstadter J, Fajgenbaum D Clin Adv Hematol Oncol. 2022; 20(9):564-571.

PMID: 36125948 PMC: 9584165.


References
1.
Beck J, Hsu S, Wijdenes J, Bataille R, Klein B, Vesole D . Brief report: alleviation of systemic manifestations of Castleman's disease by monoclonal anti-interleukin-6 antibody. N Engl J Med. 1994; 330(9):602-5. DOI: 10.1056/NEJM199403033300904. View

2.
Stahl C, Zucker-Franklin D, Evatt B, Winton E . Effects of human interleukin-6 on megakaryocyte development and thrombocytopoiesis in primates. Blood. 1991; 78(6):1467-75. View

3.
Warren M, Conroy L, Rose J . The role of interleukin 6 and interleukin 1 in megakaryocyte development. Exp Hematol. 1989; 17(11):1095-9. View

4.
Yoshizaki K, Matsuda T, Nishimoto N, Kuritani T, Taeho L, Aozasa K . Pathogenic significance of interleukin-6 (IL-6/BSF-2) in Castleman's disease. Blood. 1989; 74(4):1360-7. View

5.
Lotem J, Shabo Y, Sachs L . Regulation of megakaryocyte development by interleukin-6. Blood. 1989; 74(5):1545-51. View